Competing to Coordinate Cell Fate Decisions: the MST2-Raf-1 Signaling Device

Overview

Journal Cell Cycle

Specialty Cell Biology

Date 2015 Jan 22

PMID 25607644

Citations 17

Authors

Lan K Nguyen

David G Matallanas

David Romano

Boris N Kholodenko

Walter Kolch

Affiliations

Soon will be listed here.

Abstract

How do biochemical signaling pathways generate biological specificity? This question is fundamental to modern biology, and its enigma has been accentuated by the discovery that most proteins in signaling networks serve multifunctional roles. An answer to this question may lie in analyzing network properties rather than individual traits of proteins in order to elucidate design principles of biochemical networks that enable biological decision-making. We discuss how this is achieved in the MST2/Hippo-Raf-1 signaling network with the help of mathematical modeling and model-based analysis, which showed that competing protein interactions with affinities controlled by dynamic protein modifications can function as Boolean computing devices that determine cell fate decisions. In addition, we discuss areas of interest for future research and highlight how systems approaches would be of benefit.

Citing Articles

Enzyme Is the Name-Adapter Is the Game.

Huber M, Brummer T Cells. 2024; 13(15.

PMID: 39120280 PMC: 11311582. DOI: 10.3390/cells13151249.

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.

Bahar M, Kim H, Kim D Signal Transduct Target Ther. 2023; 8(1):455.

PMID: 38105263 PMC: 10725898. DOI: 10.1038/s41392-023-01705-z.

Meta-Dynamic Network Modelling for Biochemical Networks.

Hart A, Nguyen L Methods Mol Biol. 2023; 2634:167-189.

PMID: 37074579 DOI: 10.1007/978-1-0716-3008-2_8.

NF-kB in Signaling Patterns and Its Temporal Dynamics Encode/Decode Human Diseases.

Almowallad S, Alqahtani L, Mobashir M Life (Basel). 2022; 12(12).

PMID: 36556376 PMC: 9788026. DOI: 10.3390/life12122012.

Feedback, Crosstalk and Competition: Ingredients for Emergent Non-Linear Behaviour in the PI3K/mTOR Signalling Network.

Ghomlaghi M, Hart A, Hoang N, Shin S, Nguyen L Int J Mol Sci. 2021; 22(13).

PMID: 34203293 PMC: 8267830. DOI: 10.3390/ijms22136944.

References

Zhou D, Conrad C, Xia F, Park J, Payer B, Yin Y . Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009; 16(5):425-38. PMC: 3023165. DOI: 10.1016/j.ccr.2009.09.026. View

Nguyen L, Matallanas D, Croucher D, von Kriegsheim A, Kholodenko B . Signalling by protein phosphatases and drug development: a systems-centred view. FEBS J. 2012; 280(2):751-65. PMC: 3368988. DOI: 10.1111/j.1742-4658.2012.08522.x. View

Dhillon A, Meikle S, Yazici Z, Eulitz M, Kolch W . Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J. 2002; 21(1-2):64-71. PMC: 125807. DOI: 10.1093/emboj/21.1.64. View

Ho K, Zhou Z, She Y, Chun A, Cyr T, Yang X . Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected]. Proc Natl Acad Sci U S A. 2011; 108(12):4870-5. PMC: 3064387. DOI: 10.1073/pnas.1101273108. View

ONeill E, Kolch W . Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle. 2005; 4(3):365-7. DOI: 10.4161/cc.4.3.1531. View

Donninger H, Vos M, Clark G . The RASSF1A tumor suppressor. J Cell Sci. 2007; 120(Pt 18):3163-72. DOI: 10.1242/jcs.010389. View

Romano D, Matallanas D, Frederick D, Flaherty K, Kolch W . One Hippo and many masters: differential regulation of the Hippo pathway in cancer. Biochem Soc Trans. 2014; 42(4):816-21. DOI: 10.1042/BST20140030. View

Matallanas D, Romano D, Al-Mulla F, ONeill E, Al-Ali W, Crespo P . Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell. 2011; 44(6):893-906. DOI: 10.1016/j.molcel.2011.10.016. View

Feng X, Degese M, Iglesias-Bartolome R, Vaque J, Molinolo A, Rodrigues M . Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell. 2014; 25(6):831-45. PMC: 4074519. DOI: 10.1016/j.ccr.2014.04.016. View

10.

Couzens A, Knight J, Kean M, Teo G, Weiss A, Dunham W . Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci Signal. 2013; 6(302):rs15. DOI: 10.1126/scisignal.2004712. View

11.

Kobayashi T, Aoki Y, Niihori T, Cave H, Verloes A, Okamoto N . Molecular and clinical analysis of RAF1 in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activation. Hum Mutat. 2010; 31(3):284-94. DOI: 10.1002/humu.21187. View

12.

Andrabi S, Gjoerup O, Kean J, Roberts T, Schaffhausen B . Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner. Proc Natl Acad Sci U S A. 2007; 104(48):19011-6. PMC: 2141899. DOI: 10.1073/pnas.0706696104. View

13.

Salah Z, Melino G, Aqeilan R . Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 2011; 71(5):2010-20. DOI: 10.1158/0008-5472.CAN-10-3516. View

14.

Yeung B, Ho K, Yang X . WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS One. 2013; 8(4):e61027. PMC: 3616014. DOI: 10.1371/journal.pone.0061027. View

15.

Nguyen L, Kolch W, Kholodenko B . When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling. Cell Commun Signal. 2013; 11:52. PMC: 3734146. DOI: 10.1186/1478-811X-11-52. View

16.

Liu C, Lv X, Li T, Xu Y, Zhou X, Zhao S . PP1 cooperates with ASPP2 to dephosphorylate and activate TAZ. J Biol Chem. 2010; 286(7):5558-66. PMC: 3037669. DOI: 10.1074/jbc.M110.194019. View

17.

Hesson L, Cooper W, Latif F . The role of RASSF1A methylation in cancer. Dis Markers. 2007; 23(1-2):73-87. PMC: 3850810. DOI: 10.1155/2007/291538. View

18.

Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D . RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell. 2007; 27(6):962-75. PMC: 2821687. DOI: 10.1016/j.molcel.2007.08.008. View

19.

Ecker K, Hengst L . Skp2: caught in the Akt. Nat Cell Biol. 2009; 11(4):377-9. DOI: 10.1038/ncb0409-377. View

20.

Jiang B, Liu L . PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res. 2009; 102:19-65. PMC: 2933405. DOI: 10.1016/S0065-230X(09)02002-8. View